KZE PharmAssociates is a full service medical communications company located near the Research Triangle Park, North Carolina that provides services to the pharmaceutical and biotechnology industries.
We support developing and launched products (drugs, diagnostics, and devices) by providing:
We help you plan, develop, and implement your medical communications strategy in order to bring your product's key messages to the right audience at the right time.
We focus on the preparation of:
Medical and Regulatory Communications that include clinical trial manuscripts, review
articles, abstracts, posters and slide presentations, study reports, investigator
brochures, protocols, and informed consent forms
Strategic Documents including Publication Plans, Competitive Analyses,
Therapeutic Area Assessments, White Papers, and Case Studies
We work directly with pharmaceutical and biotechnology companies and partner with CROs, CMEs and PR firms in order to augment their internal capabilities.
KZE's principals are Ph.D. pharmacologists, each with over 30 years experience in biomedical research and communication. We have proven expertise in Pain , Oncology , diseases of the Gastrointestinal and Respiratory tracts , Anti-infectives , CNS disorders , and a broad range of technologies.
We offer our clients a comprehensive perspective on developing communication products for the lifecycle of their products. With cross-functional experience in the pharmaceutical industry, we are adept at working in international matrix-managed environments and in delivering results consistent with aggressive timelines.
KZE's principals are Ph.D. pharmacologists, each with over 20 years experience in
biomedical research and communication. We have proven in:
Expertise
Pain, Oncology, diseases of the Gastrointestinal and Respiratory tracts, Anti-infectives, CNS disorders, and a broad range of technologies.
Patrice C. Ferriola, Ph.D. is co-founder and Managing Member. Dr. Ferriola is a principal consultant, writer and project manager for KZE clients. She has broad therapeutic area expertise and is an active member of the Counsel of Science Editors and American Medical Writer’s Association. Prior to founding KZE PharmAssociates, Dr. Ferriola was Department Head of International Medical Publications for GlaxoSmithKline in Research Triangle Park, NC.
Dr. Ferriola received her B.S. in biology from SUNY at Stony Brook and her Ph.D. in pharmacology from the SUNY at Buffalo. Earlier in her career, Dr. Ferriola received NIH post-doctoral training in oncology, and was a research scientist at the National Institute of Environmental Health Science and the Chemical Industry Institute of Toxicology. She is an author on over 20 publications in oncology, gastroenterology, and respiratory peer-reviewed journals, and has written and edited numerous manuscripts, book chapters, and reports.
POSITIONS HELD
2001-present Founder and Principal, KZE PharmAssociates, LLC, Chapel Hill, NC
2000-2001 Department Head, International Medical Publications, GlaxoSmithKline, RTP, NC
1997-2000 Sr. Medical Publications Scientist, Glaxo Wellcome, RTP, NC
1996-2001 Adjunct Professor, North Carolina State University, Raleigh, NC
1993-1997 Research Scientist, Chemical Industry Institute of Toxicology, RTP, NC
1987-1993 Scientist, National Institute Environmental Health Science, RTP, NC
PROFESSIONAL ORGANIZATIONS
Council of Science Editors
Drug Information Association
American Medical Writers Association
David A. Bruckenstein, Ph.D. is co-founder and Managing Member. Dr. Bruckenstein has broad therapeutic expertise and extensive sales training and business development experience. Prior to founding KZE, Dr. Bruckenstein was Director of Business Development at GlaxoSmithKline in Research Triangle Park, NC.
Dr. Bruckenstein received his B.S. in Biology from Cornell University and his Ph.D. in Pharmacology from SUNY at Buffalo. After post-doctoral training in neurobiology, Dr. Bruckenstein was a microscopy sales associate for Nikon, Inc, a research scientist at Glaxo and Glaxo Wellcome, and founder of BioCon consulting.
In addition to being a principal consultant, writer and project manager, Dr. Bruckenstein is responsible for new client development for KZE.
2001-present Co-Founder and Principal, KZE PharmAssociates, LLC, Chapel Hill, NC
1996-2001 Director, Global Business Development, GlaxoSmithKline, RTP
1993-1996 Research Scientist and project leader , Glaxo Wellcome, RTP, NC
1992-1993 Senior Scientist, Cell Biology, Glaxo Research Institute, RTP, NC
1991-1992 President, BioCon contract research provider, Durham, NC
1990-1991 Sales Manager, Southern Micro Instruments, RTP, NC
1987- 1990 Research Fellow, Neurobiology, Glaxo, RTP, NC
Our clients typically reside in Marketing, Clinical Development, Medical Affairs,
Medical Communications, Medical Information, and Portfolio Management groups.
We tailor our services to meet your specific needs and focus our efforts
on medical and regulatory communications and strategic consulting that
support drugs, diagnostics, and devices throughout the product lifecycle.
Within each therapeutic area, we bring the experience of research directed at the
molecular mechanisms behind disease, as well as an in depth knowledge of the
relevant diseases and current treatment issues. We also have extensive experience
in commercial issues related to drug development, as well as in the regulatory and
editorial issues impacting on communicating and publishing data from clinical trials.
Add pages to your website.
1. Manage using the page manager on the right
duplicate, hide, rename, password protect & more
2. Resize pages by dragging at the edges
3. Drag & drop content in. Be sure to keep inside the page boundary
4. Add Menu from the bottom to add navigation
KZE has prepared a broad array of medical, regulatory, and strategic communication products in support of drugs developed for the treatment of asthma and COPD and for the role of tissue factor pathway inhibitors in treating sepsis in patients with community-acquired pneumonia
Medical Writing Products
Bibliography
P-F Laterre, SM Opal, E Abraham, SP et al. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Critical Care 2009, 13:R36 http://ccforum.com/content/13/2/R36 2009.
Effect of hydroxocobalamin on measurement of plasma lactate concentration: an in vitro study . Poster presentation at American College of Emergency Physicians Annual Meeting 2008. Ann Emer Med Oct 2008.
AH Hall, R Dart, G Bogdan. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? Annals Emer Med 49(6): 806-13, 2009.
FJ Baud. Cyanide: Critical issues in diagnosis and treatment. Human Exp Toxicol 26(3): 191-204, 2007.
Baud FJ, Borron S, Barriot P, Bismuth C. Plasma Lactate Concentrations as a Marker of Cyanide Poisoning in Smoke-Inhalation Victims. Poster presentation at the National Association of EMS Physicians Annual Meeting 2007. Prehosp Emer Care 11:136, 2007.
EO Meltzer, C Andrews, GE Journeay et al. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol 104(4):331-8, 2010.
EO Meltzer, J Stahlman, J Leflein, et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone paropionate nasal sprays: A randomized, multicenter, double-blind, single-dose, cross-over study. Clin Ther 30: 1-9, 2008.
AL Levy, JT Given, SF Weinstein, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in four- to eleven-year-old children with asthma: a randomized, double-blinded, placebo-controlled study. Pediatric Asthma, Allergy & Immunology 19 (2): 106 -117, 2006.
PY Qagundah, RW Sugarman, E Ceruti, et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre–school-age children with asthma: A randomized, double-blind, placebo-controlled study J Pediatrics 149, (5): 663-670, 2006.
SH Randell, JY Liu, PC Ferriola, et al. Regulation of mucin production in SPOC1 cells: an airway epithelial mucous goblet cell line. Am. J. Resp. Cell Mol. Biol. 14:146-154, 1996.
Ferriola, PC, Ambroso, JL, Patrone, et al.: Localizing and quantifying toxicological responses in lung cells with confocal laser scanning microscopy. CIIT Activities 16(6): 1-8, 1996.
MM Doherty, JY Liu, et al., and Ferriola, P.C.: Phenotype and differentiation potential of a novel airway epithelial cell line. Am. J. Resp. Cell Mol. Biol. 12:385-95, 1995.
EM Middleton, PC Ferriola, G Drzewiecki, and RD Sophia. The effect of azelastine and other anti-asthmatic and anti-allergy drugs on calmodulin and protein kinase C. Agents and Actions, 28:9-15, 1989.
EM Middleton and PC Ferriola. Effect of flavonoids on PKC: relationship to inhibition of human basophil histamine release. In: Plant Flavonoids in Biology and Medicine II: Biochemical, Cellular and Medicinal Properties, EM Middleton, V Cody and J Harborne, eds., New York: Alan R. Liss, Inc., 1988.
EM Middleton and PC Ferriola. Effect of flavonoids on protein kinase C: relationship to inhibition of human basophil histamine release. Prog Clin Biol Res 280: 251-66, 1988.
For inquiries please contact:
David Bruckenstein, Ph.D.
(919) 968-2525
